Announcement follows FDA's February 2025 decision to grantradiprodil Breakthrough Therapy designation Company remains on track to initiate Phase 3 pivotal trial ofradiprodil ...
Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and full year 2024 earnings call. At this time, all lines are in a listen only mode. Following the presentation, we will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback